Vaxart, Inc. · OTC:VXRT
Vaxart — Investor Presentation (February 2021)
25 slides from Vaxart's investor presentation, Feb 3, 2021
Slide 1: Vaxart's Oral Vaccine Candidate for Prevention of Covid-19
eabystae Vaxart’s Oral Vaccine Candidate for Prevention of Covid-19.
Slide 2: Forward-Looking Statement
Forward-Looking Statement ep “This presentation contains forward-ooking statements that involve substantial sks and uncertainties All statements, other than statements of historical facts, Included inthis presentaton regarding Vaxarts strategy, prospects, plans and objectives, results ftom predinica
Slide 3: Proprietary Oral Vaccine Platform: Vaccine Tablets
Proprietary Oral Vaccine Platform : Vaccine Tablets VAXART Intestinal Delivery + Targeted Immune Activation ee ; ened Platform: Room-temperature (25°C) ‘ Norovirus stable esi enteric-coated tablets | 7A " ov | ee ee = —_ kL 3 7 as uw ° (-vecor sant incurs oe VAAST™: Vector-Adjuvant-Antigen Standardi
Slide 4: Platform has been tested in humans for a different respiratory pathogen
Platform has been tested in humans for a different C35) respiratory pathogen VAXKART Double-Blind, Placebo-Controlled - with Active Comparator (Fluzone) + Funded by HHS/ASPR/BARDA' as innovative approach to develop more effective influenza vaccines + Three Groups received a one-time administration o
Slide 5: Influenza study adverse event table
Headache 7 (19%) 5 (7%), 6 (8%) Myalgia/body aches 1(3%) 1(1%) 0 Fever ° 2(3%) o Gastrointestinal Disorders Diarrhea 5 (14%) 4 (6%) 0 ‘Abdominal Pain 1(3%) 0 1(1%) Nausea 1(3%) 4 (6%) 3 (4%) Vomiting ° ° 1(1%) Local symptoms Pain at injection site 1 (2.8%) 2(2.9%) 10 (13.9%) Tenderness at injection
Slide 6: Reduction in Illness and Infection Rates Similar to Fluzone
Reduction in IIIness and Infection Rates Similar to Fluzone ep Reduction in Illness and Infection Rates Trended Superior to Fluzone VAXART Protection Against Illness Protection Against Infection Illness Rates Infection Rates 60% 80% so% 30% $27% cox 048% = Y 38% 40% 30% 40% (20% 10% 20% 0% 0% Vaxart
Slide 7: IgA ASC was the most important immune parameter to predict protection
IgA ASC was the most important immune parameter to predict protection from oral immunization ep VAXART * Random Forest Analysis — IgA ASC most important immunological feature for protection against shedding for the Oral Vaccine — HAI most important feature for protection against shedding for the QIV
Slide 8: Vaxart Vaccine Specifically Elicits Increased Expression of Mucosal Homing Receptor α4β7
Vaxart Vaccine Specifically Elicits Increased Expression of C35) Mucosal Homing Receptor «487 on Activated Plasmablasts = vaxant (C) 100 % 87 expressing plasmablasts 80: 60. 40: ‘of Total Plasmablasts *** P<0,0001 Liebowitz, et al, Lancet ID, 2020
Slide 9: COVID Vaccines — Where are we now?
ep COVID Vaccines — Where are we now? VAXART Vaccine developers have made advanced candidates at incredible speed Several needle-based vaccines have completed Phase 3 — Expression of the S protein in people leads to substantial protection (symptomatic illness) against matched strains (Moderna, Pfize
Slide 10: COVID-19 Vaccine Development and Distribution Efforts are Being Outpaced by Rapidly Emergent Strains
COVID-19 Vaccine Development and Distribution Efforts C35) are Being Outpaced by Rapidly Emergent Strains VAXART Nsory eye South African Rapid Emergence of rib 3 strain new SARS-CoV? strains | ———» algal spel <™s™ - New mutations are starting to accumulate in the S1/RBD domain, where neutralizing an
Slide 11: Rate Limiting Step is the time for injected large populations: Vaxart Takes Away the Needles
Rate Limiting Step is the time for injected large C35) populations: Vaxart Takes Away the Needles VAXART Rapid Emergence of new SARS-CoV-2 strains Get Off The Wheel — Shorten the Time to Herd Immunity Soo Vaxart’s solution - Room temperature stable tablet, easy to produce, distribute, and administer
Slide 12: Goal: Drive CD8 T cell responses and mucosal responses with our Covid-19 vaccine candidate
Goal: Drive CD8 T cell responses and mucosal C35) responses with our Covid-19 vaccine candidate VAXART Candidate VXA-CoV2-1 * Expressing both S and N proteins — Sis good antibody target, but also has a lot of T cell epitopes — Nis more conserved anda good target for T cell responses * Made several d
Slide 13: Oral COVID-19 vaccine candidate induces potent antibody responses in hamsters
Oral COVID-19 vaccine candidate induces potent antibody responses in C35) hamsters VAXART Serum IgG ant-S ELISA + Oral administration induced specific A VXACOV2.A In, antibody titers above : | = Never 10,000 over = background — a) ne * Oral administration frnmnice f fenatenge performed as well as Ta
Slide 14: Oral COVID-19 vaccine protects against weight loss in a hamster challenge model
Oral COVID-19 vaccine protects against a key clinical outcome, weight losseGEB in a hamster challenge model VAXART The Syrian hamster is a very sensitive COVID-19 model 9) Post Challenge Body Weights (Mean + SEM) + Syrian hamsters have an = ACE2 receptor that can BE bind SARS-CoV-2 3 2 = AdSNoral +
Slide 15: Orally vaccinated hamsters protected against lung COVID-19 infection
Orally vaccinated hamsters protected against lung COVID-19 infection as C35) measured by qRT-PCR VAXART 4-5 logs reduction in lung viral load in hamsters that received two oral vaccine doses as compared to non-vaccinated animals RT-PCR Lung Data fa Pst Chalenge in Hamsters 100. &. Ee Oral administra
Slide 16: VXA-COV2-101 Phase 1 Study Design and Schema
ep VXA-COV2-101 Phase 1 Study Design and Schema VAXART * Single Dose, Oral Tablet Study at Low and Medium Doses * Small Sentinel Cohort that was boosted * Primary (Safety) and Secondary (Immunogenicity) Endpoints Met Treatment Group Vaccine Dose (+0.5 log) No.of Doses | No.of Subjects [erates] vacon
Slide 17: Solicited Symptoms Post Vaccination
Solicited Symptoms Post Vaccination ep VAXART Solicited Symptom Low Dose Days (1~8) 10 (66.7) Gastrointestinal Symptoms Diarrhea 0 (00) 4 (26.7) Nausea 0 (00) 5 (33.3) Vomiting 0 (00) ® ‘Abdominal Pain 1(5.0) 2(133) General Symptoms Malaise/Fatigue 2 (10) 2 (13.3) Myalgia (Muscle Pain) 1(5.0) 1(6.7)
Slide 18: Vaxart's oral vaccine shows preferential Th1 responses, inducing a strong CD8 cytotoxic response
Vaxart’s oral vaccine shows preferential Th1 responses, C35) inducing a strong CD8 cytotoxic response VAXART Spike protein (S) Nucleoprotein (N) 20: 20. a ~ a a Fold change from baseline = 3 a Fold change from baseline 3 D> DB ND WD or ar VY VLE SS Cytokine n2 cytokines are CDA+T o mele.
Slide 19: Vaxart's Oral Vaccine generates robust CD8 T cell responses
Vaxart’s Oral Vaccine generates robust CD8 T cell responses ep VAXART Vaxart’s Oral Vaccine generates high numbers of S specific IFN-y, TNFa. and CD107a producing T cells post immunization. % CD8+ lymphocytes 10 IFN-y x % CD8+ lymphocytes 30. IFNg ‘TNFa Cytokine © 00 cpto7a
Slide 20: Why T cells may be important for COVID
Why T cells may be important for COVID VAXART * Cross-protective * Long-lasting * Reduces severity and length of the infection * Mucosal T cells may be capable of blocking shedding and transmission * Higher T cell responses correlated to protection against COVID disease in in prospective study of fi
Slide 21: B cell Responses to Oral Immunization
B cell Responses to Oral Immunization C35) VAXART Sharp increase in plasmablast frequencies on day 8 after vaccination N percentage of vaccinees with cb >2 fold increase in PB frequencies So 3.3 median fold change Frequency of plasmablasts (fold change over baseline) day 8
Slide 22: Vaccine-induced plasmablasts preferentially express IgA and upregulate Mucosal Homing Receptor α4β7
Vaccine-induced plasmablasts preferentially express IgA and upregulate the Mucosal Homing Receptor 0487, C35) particularly at higher dose VAXART Before vaccination 2 cores = coor & * Ee om r¢ oo ny ] =_ aS a r 3 23 6 | Ge ag i i Oo 4 @ ts 3 Day | neff wren a$ teen” Meynewacwacr nic) go CD38 B7 SD ba
Slide 23: 52% of participants showed 2-fold or above increase in specific IgA to RBD, S, or N
52% of participants showed 2-fold or above increase in C35) specific IgA to RDB, S, or N VAXART RBD s N Any responses | responses | responses | response 16/35 11/35 13/35 18/35 Preliminary Data Responses calculated as a 2 or higher fold increase at d29 above pre-vaccination baseline measured in nasa
Slide 24: 100% of participants given two doses had an increase in specific IgA
100% of participants given two doses had an increase in C35) specific IgA in one or more compartments VAXART 6 . 54 444 a o Serum = 33H © Nasal 2 ° ° . . ° Pg ° s N RED Preliminary Data Antigen Fold rise d1 to d57 in serum and nasal IgA. 100% had a fold rise above 1.5 times pre- vaccination levels i
Slide 25: Vaxart Strategy for COVID
Vaxart Strategy for COVID VAXART Summary for VXA-CoV2-1 ° Met Primary and Secondary Endpoints — Well-tolerated = Easy to distribute and administer (Tablets) — Highly immunogenic on eliciting T cells — Dose dependent responses observed with B cells * Formulation and dosing will be evaluated in subseq